Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cardiff Oncology, Inc. Director's Dealing 2021

Jun 14, 2021

33967_dirs_2021-06-14_3170c808-7af9-458f-8c3a-1806fdbba5c7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cardiff Oncology, Inc. (CRDF)
CIK: 0001213037
Period of Report: 2021-06-10

Reporting Person: Kelemen Vicki (Exec. VP and COO)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-06-10 Stock Options $7.98 A 200928 Acquired 2031-06-10 Common Stock (200928.0) Direct

Footnotes

F1: 50,232 vest on 6/10/2022. 4,186 vest monthly for 36 months beginning on 7/10/2022 through 6/10/2025.